Oct 15th 2013 - Edison Investment Research today published a report on Prosensa entitled "Tragedy And Hope". In summary, the report says:
Drisapersen's Phase III in Duchenne muscular dystrophy (DMD) failed to show any efficacy. This was in contrast to earlier studies with encouraging results, including a Phase II open-label extension study in which the majority of 10 male patients stabilised over almost four years; they are now denied the drug until further analyses are available. Current Prosensa candidates based on newer molecular chemistries appear to have higher efficiency. It will be some time before anyone knows. GSK's support may quietly wither, as its involvement rests on exercising its option to license a further product; abrupt cancellation looks unlikely.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »